Genetic Basis and Therapies for Vascular Anomalies-Reference-Cited by-同舟云学术

Genetic Basis and Therapies for Vascular Anomalies

Published:2021-06-25 Issue:1 Volume:129 Page:155-173
ISSN:0009-7330
Container-title:Circulation Research
language:en
Short-container-title:Circ Res

Author:

Queisser Angela¹^ORCID,Seront Emmanuel²³⁴^ORCID,Boon Laurence M.¹²⁴^ORCID,Vikkula Miikka¹²⁵⁵⁶^ORCID

Affiliation:

1. Human Molecular Genetics, de Duve Institute, University of Louvain, Brussels, Belgium (A.Q., L.M.B., M.V.), University of Louvain, Brussels, Belgium (M.V.).

2. Centre for Vascular Anomalies, Division of Plastic Surgery, Cliniques Universitaires Saint-Luc Brussels, Belgium (E.S., L.M.B., M.V.)

3. Institut Roi Albert II, Department of Medical Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium (E.S.)

4. VASCERN VASCA European Reference Centre Cliniques Universitaires Saint-Luc, Brussels, Belgium (E.S., L.M.B., M.V.).

5. University of Louvain, Brussels, Belgium (M.V.).

6. Walloon Excellence in Life Sciences and Biotechnology (WELBIO), University of Louvain, Brussels, Belgium (M.V.).

Abstract

Vascular and lymphatic malformations represent a challenge for clinicians. The identification of inherited and somatic mutations in important signaling pathways, including the PI3K (phosphoinositide 3-kinase)/AKT (protein kinase B)/mTOR (mammalian target of rapamycin), RAS (rat sarcoma)/RAF (rapidly accelerated fibrosarcoma)/MEK (mitogen-activated protein kinase kinase)/ERK (extracellular signal-regulated kinases), HGF (hepatocyte growth factor)/c-Met (hepatocyte growth factor receptor), and VEGF (vascular endothelial growth factor) A/VEGFR (vascular endothelial growth factor receptor) 2 cascades has led to the evaluation of tailored strategies with preexisting cancer drugs that interfere with these signaling pathways. The era of theranostics has started for the treatment of vascular anomalies. Registration: URL: https://www.clinicaltrialsregister.eu ; Unique identifier: 2015-001703-32.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology

Reference165 articles.

1. Mulliken and Young's Vascular Anomalies

2. Glomuvenous Malformation (Glomangioma) and Venous Malformation

3. New and Emerging Targeted Therapies for Vascular Malformations

4. Vascular Dysmorphogenesis Caused by an Activating Mutation in the Receptor Tyrosine Kinase TIE2

5. Theranostic Advances in Vascular Malformations

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Basis and Diagnostic Approach to Isolated and Syndromic Lateralized Overgrowth in Childhood;The Journal of Pediatrics;2024-11

2. Vascular Anomalies and Congenital Infiltrating Lipomatosis May Affect Dental Maturation and Development – a Case Control Study;The Cleft Palate Craniofacial Journal;2024-09-12

3. CD26 Is Differentially Expressed throughout the Life Cycle of Infantile Hemangiomas and Characterizes the Proliferative Phase;International Journal of Molecular Sciences;2024-09-10

4. Somatic Loss-of-Function PIK3R1 and Activating Non-hotspot PIK3CA Mutations Associated with Capillary Malformation with Dilated Veins (CMDV);Journal of Investigative Dermatology;2024-09

5. Dysfunctional mechanotransduction regulates the progression of PIK3CA-driven vascular malformations;2024-08-23